Catalyst Wire Dossier Catalyst Wire Dossier

Leuprolide mesylate (LMIS 25 mg)

leuprolide mesylate · Foresee Pharmaceuticals Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Leuprolide mesylate (LMIS 25 mg), covering 2020-05-04 to 2020-05-04. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer [Phase 3]

See pricing